Glas, Martin and Koch, Horst and Hirschmann, Birgit and Jauch, Tanja and Steinbrecher, Andreas and Herrlinger, Ulrich and Bogdahn, Ulrich and Hau, Peter (2007) Pegylated liposomal doxorubicin in recurrent malignant glioma: Analysis of a case series. ONCOLOGY, 72 (5-6). pp. 302-307. ISSN 0030-2414,
Full text not available from this repository. (Request a copy)Abstract
Background: Recurrent malignant glioma has a dismal prognosis, and therapeutic options are scarce. After previous potentially encouraging reports on liposomal pegylated doxorubicin (PEG-DOX) in this setting, PEG-DOX was applied to patients with recurrent malignant glioma in an institutional series. Methods: In a retrospective analysis, 49 patients with recurrent high-grade glioma (WHO III, n = 18; WHO IV, n = 31) were treated with PEG-DOX (days 1 and 14/28, 20 mg/m(2), n = 26) alone or in combination with temozolomide (days 1-5/28, 200 mg/m(2), n = 23). The response rate, progression-free survival and overall survival were evaluated. Results: The rate of progression-free patients at 6 months after initiation of therapy was 27% (WHO III, 33%; WHO IV, 23%). The median overall survival (mOS) after initiation of PEG-DOX (monotherapy and combination therapy) was 8 months (WHO III, 16 months; WHO IV, 7 months). The mOS after initiation of PEG-DOX monotherapy was 8 months, and after initiation of combination therapy, 10 months. Both regimens were well tolerated, with the main side effect being hematologic toxicity (grade 1-2, 8%; grade 3-4, 18%). Conclusion: These data demonstrate the safety and moderate efficacy of PEG-DOX +/- temozolomide therapy in recurrent malignant glioma. The potential of this nonalkylating chemotherapy should be further explored. Copyright (C) 2008 S. Karger AG, Basel.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | HIGH-GRADE GLIOMA; PHASE-II TRIAL; GLIOBLASTOMA-MULTIFORME; ANAPLASTIC ASTROCYTOMA; 1ST RELAPSE; TEMOZOLOMIDE; EFFICACY; CRITERIA; malignant glioma; anaplastic astrocytoma; glioblastoma; pegylated liposomal doxorubicin; temozolomide |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 13 Jan 2021 11:14 |
| Last Modified: | 13 Jan 2021 11:14 |
| URI: | https://pred.uni-regensburg.de/id/eprint/33498 |
Actions (login required)
 |
View Item |
